What Is BCG Treatment for Bladder Cancer?
Reading tools
In this article
What Is BCG?
Bacillus Calmette–Guérin (BCG), Mycobacterium bovisin attenuated form, has been used as a tuberculosis vaccine since 1921 and, since the 1970s, for non-muscle-invasive bladder cancer (NMIBC) as a standard intravesical immunotherapy.
How Does It Work?
- Immune activation: TLR/PRR stimulation in bladder epithelium → increased IL-2, IL-12, IFN-γ, TNF-α .
- Cellular response: Activation of macrophages, dendritic cells, CD4⁺/CD8⁺ T cells, and NK cells → tumor lysis.
- Memory effect: Repeated administration produces long-term antitumor immunity.
Treatment Goals
- Clear microscopic residual disease; reduce recurrence and progression risk,
- Delay or prevent radical cystectomy,
- Provide long-term bladder tumor control and quality of life.
Approved Indication and Clinical Role
- Indication: Intermediate/high-risk NMIBC (high-grade Ta/T1, CIS).
- Guidelines (EAU, NCCN 2025): BCG is recommended as first-line intravesical treatment after TUR-M in high-risk disease.
- Clinical role: Induction + up to 3 years of maintenance is the strongest recurrence-prevention approach.
Dose and Administration Schedule
| Phase | Administration Schedule | Note |
|---|---|---|
| Induction | 1 × weekly for 6 weeks | Start ~2–3 weeks after TUR-M. |
| Maintenance | 3-week courses at months 3, 6, 12, 18, 24, 30, and 36 (SWOG) | A total of 3 years is recommended, depending on tolerability. |
| Dose | ~50 mg (10⁸–10⁹ CFU) intravesically | Retain in the bladder for 60–120 min; sterile conditions are essential. |
Urine culture must be negative beforehand; postpone for visible hematuria or traumatic catheterization.
Administration Precautions
- Aseptic administration and personal protective equipment are essential.
- Antibiotic use beforehand (particularly antituberculosis drugs) may reduce BCG efficacy → avoid if possible.
- Traumatic catheterization/hematuria → postpone administration.
- During the first 24 hours, drink plenty of fluids and decontaminate urine-contact surfaces with 5% hypochlorite.
Pretreatment Checks and Monitoring Between Visits
- Baseline: Urinalysis + culture, CBC, CRP, LFT; baseline cystoscopy/cytology.
- Each cycle: Check fever/dysuria/hematuria; culture if needed.
- Follow-up: Months 0–24: Cystoscopy ± cytology every 3 months; months 24–60: every 6 months.
Patient Selection Criteria
- Intermediate/high-risk NMIBC after TUR-M (high-grade Ta/T1, CIS).
- No active UTI; able to tolerate catheterization.
- No contraindications related to immunosuppression/systemic TB.
Drug Interactions
- Antituberculosis drugs/long-term antibiotics: May reduce BCG viability.
- Immunosuppressants (steroids, biologics): Systemic infection risk ↑.
- Other intravesical chemotherapy: Do not administer concurrently; allow 1–2 weeks between treatments.
Side Effects and Management
| Side Effect | Frequency | Management |
|---|---|---|
| Irritative lower urinary tract symptoms | 60–70% | NSAIDs, bladder analgesics; hydration. |
| Transient fever <38.5 °C | 20–30% | Antipyretic; withhold for 24 hours; culture if persistent. |
| Cystitis / granulomatous prostatitis | 10–15% | Short antibiotic course; symptom control. |
| BCG sepsis | <1% | Emergency: Stop BCG; isoniazid+rifampicin+ethambutol (≈6 months) and infectious disease consultation. |
Serious systemic complications are rare (~0.4–1.0%); early recognition and treatment are vital.
Dose Modifications
- Moderate cystitis: Reduce the next dose by 50% or postpone for 1 week.
- Fever ≥38.5 °C for >48 hours: Stop BCG; reassess after excluding infection.
- Suspected sepsis: Permanently stop BCG; start antituberculosis treatment (RIPE-derived regimens).
New Studies and Alternatives to This Treatment
Adstiladrin® (Nadofaragene firadenovec) — gene-based intravesical therapy
- An adenoviral vector triggers bladder-cell IFN-α2b production; administered 1 time every 3 months.
- In BCG-unresponsive CIS (± papillary disease), FDA-approved (2022).
- Real-world and phase 3 data show ~50% complete responseand ~24% at 12 months with an ongoing response.
Pembrolizumab (Keytruda®) — systemic immunotherapy
- PD-1 inhibitor; IV every 3–6 weeks; for BCG-unresponsive high-risk CIS, FDA-approved.
- ~40% complete response; median response duration ≈16 months; prolonged responses possible.
UGN-102 (Mitomycin C hydrogel) — gel/sustained-release intravesical therapy
- Thermoreactive gel; ~6-hour bladder residence → increased tissue contact.
- Focused on low-/intermediate-risk Ta; in 2025, FDA approval was expected with promising phase 3 (ENVISION) data.
Gemcitabine + Docetaxel — sequential intravesical chemotherapy
- "Iowa protocol"; after recurrence following BCG, at 12 months: 50–60% recurrence-free.
Other research
- CG0070 (oncolytic adenovirus+GM-CSF)—phase 3 ongoing in BCG-refractory CIS.
- BCG + Nivolumab (CheckMate 9UT)—combination immunotherapy; phase 3.
- TAR-200 —a bladder-implanted sustained-release gemcitabine device; in advanced trials.
References
- NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer, v2.2025.
- EAU Guidelines on Non–Muscle-Invasive Bladder Cancer, 2025.
- Boorjian SA et al. Lancet Oncol 2023;24(5):563–576. (Adstiladrin phase 3)
- Balar AV et al. J Clin Oncol 2021;39:2475–2486. (Pembrolizumab)
- Packiam VT et al. J Urol 2024;211(5):975–983. (UGN-102 ENVISION)
- Steinberg RL et al. J Urol 2021;205:124–133. (Gemcitabine–Docetaxel)
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.